Blood SOD1 Activity in ALS Patients Receiving Tofersen Treatment
Annals of Neurology · 11.08.2026
DOI: 10.1002/ana.78328 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Neurology, online erschienen am 11.08.2026. Verfasst von Katharina Goehring und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Ulm University Hospital, Ulm, Germany. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
The antisense oligonucleotide tofersen is the first disease‐modifying drug for SOD1‐related amyotrophic lateral sclerosis (ALS) and was approved because of its ability to reduce SOD1 protein and neurofilament levels. The effect of tofersen on SOD1 activity is unclear but of clinical relevance because homozygous SOD1 mutations, linked to reduced SOD1 activity, cause severe motor neuron impairment and tofersen‐induced reduction could be deleterious. Therefore, monitoring of SOD1 activity is urgently needed.
Methods
SOD1 activity was analyzed in blood samples from a discovery (n = 120) and a validation cohort (n = 208), including controls, patients with sporadic ALS (sALS), C9orf72 mutation carriers (c9ALS), asymptomatic (SOD1‐asym), and symptomatic SOD1 mutation carriers (SOD1‐ALS). SOD1 activity was characterized in 18 patients receiving tofersen treatment.
Results
SOD1 activity was significantly lower in both SOD1‐asym (median = 7.5 U/mg, interquartile range [IQR] = 7.0–9.0 U/mg) and SOD1‐ALS (median = 7.9 U/mg, IQR = 7.1–9.1 U/mg) relative to controls (median = 9.2 U/mg, IQR = 8.9–10.0 U/mg, p < 0.0001), c9ALS (median = 9.4 U/mg, IQR = 8.9–10.2 U/mg, p < 0.0001) and sALS (median 9.5 U/mg, IQR 8.8–9.9 U/mg, p < 0.0001). SOD1 activity was significantly lower in individuals with deleterious SOD1 variants than in individuals with neutral variants. During tofersen treatment, neurofilament and SOD1 protein levels decreased, whereas SOD1 activity remained stable.
Interpretation
The data indicate that the positive tofersen treatment effect is independent of SOD1 activity. Lower SOD1 activity is specific to SOD1‐ALS, already present in the asymptomatic phase and depends on the mutation type. Future studies should determine whether tofersen treatment affects cerebrospinal fluid (CSF) SOD1 activity. ANN NEUROL 2026
Autor:innen und Institutionen
- Department of Neurology, Ulm University Hospital, Ulm, Germany.
- German Center for Neurodegenerative Diseases (DZNE) Ulm, Ulm, Germany.
- Department of Neurology, Hannover Medical School, Hannover, Germany.
- Department of Molecular Neurology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
- Department of Neurology with Friedrich-Baur-Institute, LMU University Hospital, LMU Munich, München, Germany.
- PRACTIS Clinician Scientist Program, Dean's Office for Academic Career Development, Hannover Medical School, Hannover, Germany.
ORCID-Profile: Johannes Dorst, Martin Regensburger, Markus Otto, Patrick Oeckl
Zitieren
APA
Goehring, K., Abler, E., Vavra, J., Mayer, K., Dorst, J., Elmas, Z., Wiesenfarth, M., Richter, L., Petri, S., Regensburger, M., Reilich, P., Bjelica, B., Lumi, R., Süß, P., Tumani, H., Otto, M., Weishaupt, J. H., Ludolph, A. C., & Oeckl, P. (2026). Blood SOD1 Activity in ALS Patients Receiving Tofersen Treatment. Annals of Neurology. https://doi.org/10.1002/ana.78328
Vancouver
Goehring K, Abler E, Vavra J, Mayer K, Dorst J, Elmas Z, et al. Blood SOD1 Activity in ALS Patients Receiving Tofersen Treatment. Annals of Neurology. 2026. doi:10.1002/ana.78328
BibTeX
@article{Goehring2026,
author = {Goehring, Katharina and Abler, Enya and Vavra, Jakub and Mayer, Kristina and Dorst, Johannes and Elmas, Zeynep and Wiesenfarth, Maximilian and Richter, Lars and Petri, Susanne and Regensburger, Martin and Reilich, Peter and Bjelica, Bogdan and Lumi, Rea and Süß, Patrick and Tumani, Hayrettin and Otto, Markus and Weishaupt, Jochen H and Ludolph, Albert C and Oeckl, Patrick},
title = {Blood SOD1 Activity in ALS Patients Receiving Tofersen Treatment},
journal = {Annals of Neurology},
year = {2026},
doi = {10.1002/ana.78328}
}
EUVIMED